Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
Market Cap | 849.645 Million | Shares Outstanding | 144.497 Million | Avg 30-day Volume | 1.724 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -2.44 |
Price to Revenue | 3051.9031 | Debt to Equity | 0.0 | EBITDA | -341.942 Million |
Price to Book Value | 1.2058 | Operating Margin | -151507.265 | Enterprise Value | 189.009 Million |
Current Ratio | 8.08 | EPS Growth | -0.109 | Quick Ratio | 7.908 |
1 Yr BETA | 1.4855 | 52-week High/Low | 17.49 / 4.42 | Profit Margin | -150207.6923 |
Operating Cash Flow Growth | -7.4612 | Altman Z-Score | -0.6255 | Free Cash Flow to Firm | -207.412 Million |
Earnings Report | 2023-08-08 |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
MOORE TIMOTHY L. CHIEF TECHNICAL OFFICER |
|
0 | 2023-04-24 | 2 |
SMITH LILLIAN VP, CORPORATE COUNSEL |
|
83,845 | 2023-04-01 | 2 |
|
8,358,208 | 2023-03-22 | 1 | |
CHANG DAVID D PRESIDENT AND CEO |
|
6,251,063 | 2023-03-22 | 2 |
SCHMIDT ERIC THOMAS CHIEF FINANCIAL OFFICER |
|
2,015,034 | 2023-03-22 | 2 |
MOORE ALISON CHIEF TECHNICAL OFFICER |
|
672,731 | 2023-03-22 | 2 |
ROBERTS ZACHARY EVP OF R&D |
|
399,943 | 2023-03-22 | 3 |
BHAVNAGRI VEER GENERAL COUNSEL |
|
556,049 | 2023-03-14 | 4 |
AMADO RAFAEL EVP OF R&D |
|
541,946 | 2022-10-07 | 5 |
|
218,271 | 2022-08-11 | 4 | |
|
0 | 2022-07-08 | 2 | |
|
76,986 | 2022-06-15 | 1 | |
|
303,063 | 2022-06-15 | 1 | |
|
191,892 | 2022-06-15 | 1 | |
|
77,605 | 2022-06-15 | 1 | |
|
71,070 | 2022-06-15 | 1 | |
|
0 | 2022-03-31 | 0 | |
|
18,716,306 | 2022-01-12 | 0 | |
|
18,716,306 | 2020-08-06 | 0 | |
|
22,032,040 | 2018-10-15 | 0 | |
|
0 | 2018-10-10 | 0 | |
|
0 | 2018-10-10 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-04-26 17:20:45 -0400 | 2023-04-24 | A | 186,219 | a | 186,219 | direct | 2.0677 | 21.2406 | 21.2406 | 6 | 0.0 | 1 | ||||
2023-04-26 17:20:45 -0400 | 2023-04-24 | A | 831,024 | a | 831,024 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 22:15:04 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 21:45:05 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 21:15:04 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 20:45:04 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 20:15:06 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 19:45:04 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 19:15:04 UTC | 4.4263 | 0.6437 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 18:45:04 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 18:15:03 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 17:45:05 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 17:15:04 UTC | 4.4606 | 0.6094 | 1300000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 16:45:03 UTC | 4.4606 | 0.6094 | 1300000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 16:15:04 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 15:45:04 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 15:15:04 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 14:45:04 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 14:15:03 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 13:45:03 UTC | 4.4606 | 0.6094 | 600000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 13:15:04 UTC | 4.4606 | 0.6094 | 1300000 |
ALLOGENE THERAPEUTICS INC ALLO | 2023-06-07 12:45:04 UTC | 4.4606 | 0.6094 | 1300000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AGF Investments Trust- AGFIQ U.S. Market Neutral Value Fund | ALLO | -87.0 shares, $-3280.77 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Defensive Long Fund | ALLO | -80.0 shares, $-1555.2 | 2020-03-31 | N-PORT |
FundVantage Trust- Gotham Master Neutral Fund | ALLO | -44.0 shares, $-1659.24 | 2020-09-30 | N-PORT |
FundVantage Trust- Gotham Index Plus All-Cap Fund | ALLO | -161.0 shares, $-3129.84 | 2020-03-31 | N-PORT |
Trust for Professional Managers- Convergence Long/Short Equity Fund | ALLO | -2326.0 shares, $-43007.74 | 2021-11-30 | N-PORT |
FundVantage Trust- Gotham Hedged Plus Fund | ALLO | -1016.0 shares, $-6390.64 | 2022-12-30 | N-PORT |